This article is part of the supplement: Proceedings of Delivery Systems and Current Strategies to Drug Design

Open Access Proceedings

A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models

Sonsire Fernández*, Esther M Fajardo, Aleida Mandiarote, Gemma Año, Maria A Padrón, Michel Acosta, Rubén A Cabrera, Luis A Riverón, Maydelis Álvarez, Kirenia Blaín, Mildrey Fariñas, Daniel Cardoso, Luis G García, Concepción Campa and José L Pérez

Author Affiliations

Research & Development Vice-presidency, Finlay Institute. Havana, Cuba

For all author emails, please log on.

BMC Immunology 2013, 14(Suppl 1):S8  doi:10.1186/1471-2172-14-S1-S8

Published: 25 February 2013


Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the potential of proteoliposomes (PL) extracted from Bordetella pertussis as a vaccine candidate against whooping cough. The size of the B. pertussis PL was estimated to be 96.7±50.9 nm by Scanning Correlation Spectroscopy and the polydispersity index was 0.268. Western blots using monoclonal antibodies revealed the presence of pertussis toxin, pertactin, and fimbriae 3. The Limulus Amebocyte Lisate (LAL) assay showed endotoxin levels lower than those reported for whole cell pertussis licensed vaccines, while the Pyrogen Test indicated 75 ng/mL/Kg. The PL showed high protection capacity in mouse challenge models. There was 89.7% survival in the intracerebral challenge and total reduction of the number of CFU in the intranasal challenge. No significant differences (p>0.05) were observed between mice immunized with B. pertussis PL and the Cuban DTwP vaccine, whichever challenge model used. These results encouraged us to continue the development of the B. pertussis PL as a component of a new combined vaccine formulated with tetanus and diphtheria toxoids or as a booster dose for adolescents and adults.